Login to Your Account



Financings Roundup

Alnylam Flexes Fundraising Muscles, Adds $80M Publicly

By Catherine Shaffer
Staff Writer

Thursday, February 16, 2012
Alnylam Pharmaceuticals Inc.'s underwritten public offering of 7.5 million shares at $10.75 apiece sent shares of the Cambridge, Mass.-based biotech surging more than 14 percent Wednesday as investors showed their approval of its pipeline and partnering power.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription